Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Confluence Pharmaceuticals

Confluence Pharmaceuticals
2010 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$805K LATEST DEAL AMOUNT
3 INVESTORS
Description

Developer of therapeutic medications intended for neurological development disorders. The company' focuses on therapeutic drug development, enabling patients to get medications to treat core social, communication and cognitive impairments associated with Fragile X Syndrome and Autism Spectrum Disorders.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Primary Office
  • 4904 Deer Ridge Drive South
  • Carmel, IN 46033
  • United States

+1 (317) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Confluence Pharmaceuticals’s full profile, request a free trial.

Confluence Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 30-May-2019 $805K 00.000 Completed Generating Revenue
2. Later Stage VC 03-Oct-2018 0000 00.000 Completed Generating Revenue
1. Later Stage VC (Series A2) 07-Nov-2017 $1.3M $1.3M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Confluence Pharmaceuticals Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Janssen Research and Development Corporate Backed or Acquired Titusville, NJ 000000&0
00000000 000000000 Formerly VC-backed Marlborough, MA 0000 000000&0
00000000 Corporation Valby, Denmark 0000
00000000 Venture Capital-Backed Baltimore, MD 0 000.00 0000000000 000.00
000000 00000000000 Corporation Freemans Bay, New Zealand 0
To view this company’s complete list of competitors, request access »

Confluence Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Foundry Partners PE-Backed Company Minority 000 0000 000000 0
Indiana University Philanthropic Venture Fund Other Minority 000 0000 000000 0
Elevate Ventures Venture Capital Minority 000 0000 000000 0

Confluence Pharmaceuticals Executive Team (5)

Name Title Board
Seat
Contact
Info
Steven Johns Co-Founder, Chief Executive Officer, President & Board Member
Kenneth Payie Ph.D Director of Chemistry, Manufacturing & Controls
Timothy Parshall Vice President of Corporate Affairs
Sharon Rosenzweig-Lipson Ph.D Vice President of Research
Craig Erickson MD Lead Scientific Advisor

Confluence Pharmaceuticals Board Members (3)

Name Representing Role Since Contact
Info
Boyd Sturdevant Jr. Confluence Pharmaceuticals Co-Founder and Chairman 000 0000
Phil Lodato JD Elevate Ventures Board Member 000 0000
Steven Johns Confluence Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000